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The HOX genes are a family of homeodomain-containing transcription factors that determine the identity of cells and tissues during
embryonic development. They are also known to behave as oncogenes in some haematological malignancies. In this study, we show
that the expression of many of the HOX genes is highly elevated in primary non-small-cell lung cancers (NSCLCs) and in the derived
cell lines A549 and H23. Furthermore, blocking the activity of HOX proteins by interfering with their binding to the PBX co-factor
causes these cells to undergo apoptosis in vitro and reduces the growth of A549 tumours in vivo. These findings suggest that the
interaction between HOX and PBX proteins is a potential therapeutic target in NSCLC.
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The HOX genes are a family of homeodomain-containing
transcription factors that determine the identity of cells and
tissues in early development (Iimura and Pourquie ´, 2007), and also
have key regulatory roles in adult haematopoietic stem cells and
their descendants (Abramovich and Humphries, 2005). In addi-
tion, HOX genes are often overexpressed in malignant cells and are
known to act as oncogenes in some haematopoietic malignancies
(Eklund, 2007).
Repeated duplication events have given rise to 39 HOX genes in
mammals, divided into four groups (A–D) in tightly linked
clusters on different chromosomes (Hoegg and Meyer, 2005). The
HOX genes are also divided into paralogue groups – genes that
have the equivalent position in each cluster (1–13) – thus HOXA1,
for example, is the 30 most gene in cluster A (Scott, 1993). Whereas
some HOX genes have distinct functions in specific contexts, many
others have overlapping or redundant functions, both during early
development (McIntyre et al, 2007) and in malignant cells (Eklund,
2007). This redundancy in HOX function is based in part upon the
binding of similar DNA sequences and also on the interaction of
HOX proteins with a common set of co-factors including PBX and
MEIS. PBX and MEIS modify the DNA-binding specificity of HOX
proteins, influence the regulation of transcription and are required
for many aspects of HOX function (Moens and Selleri, 2006).
In addition to haematological malignancies, the HOX genes are
also expressed at high levels in many other solid malignancies,
although with the exception of melanoma (Morgan et al, 2007),
they are not known to have an oncogenic function. A number of
studies, focusing on small groups of HOX genes, have shown that
some are upregulated in lung cancer (Abe et al, 2006), but the
functional significance of this is unknown. Here we present a
comprehensive analysis of HOX expression in non-small-cell lung
cancer (NSCLC) that reveals that many of the HOX genes have
strongly elevated expression in malignant cells. Further, we show
that antagonising HOX/PBX binding in the NSCLC cell lines A549
(Lieber et al, 1976) and H23 (Little et al, 1983) induces apoptosis
in vitro and causes significant tumour shrinkage in A549 nude
mouse models.
MATERIALS AND METHODS
Maintenance of A549 and H23 in culture
The NSCLC cell lines A549 and H23 were obtained from the
American Type Culture Collection (ATCC, Manassas, VA, USA).
The cells were cultured in F-12K Nutrient Mixture Kaighn’s
Modification medium (Invitrogen, Paisley, UK) supplemented with
10% foetal calf serum (Invitrogen) and 1% penicillin (10000Uml
 1)/
streptomycin (10mgml
 1) (Sigma, Gillingham, UK). Cell cultures
were maintained at 371C in a humidified, 5% CO2 incubator.
Synthesis of HXR9 and CXR9 peptides
HXR9 is an 18-amino-acid peptide consisting of the previously
identified hexapeptide sequence that can bind to PBX and nine
C-terminal arginine residues (R9) that facilitate cell entry (Morgan
et al, 2007). The N-terminal and C-terminal amino bonds are in the
D-isomer conformation, which has earlier been shown to extend
the half-life of the peptide to 12h in human serum (Morgan et al,
2007). CXR9 is a control peptide that lacks a functional
hexapeptide sequence and that includes the R9 sequence. All
peptides were synthesised using conventional column-based
chemistry and purified to at least 80% (Biosynthesis Inc.,
Lewisville, TX, USA).
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sImaging of cell cultures
Cells were plated in six-well plates in 2ml of medium and allowed
to recover for at least 24h. When approximately 60% confluent,
the cells were treated with the active peptide HXR9 (60mM) or the
control peptide CXR9 (60mM) for 3h. For phase-contrast micro-
graphs, the cells were washed twice with cold PBS and visualised
using a Nikon Eclipse TS100 inverted microscope and images
recorded using a Nikon camera and capture software (Jencons).
Analysis of cell death and apoptosis
Cells were treated with HXR9 or CXR9 as described above.
Assessment of cell viability was performed using the MTS assay
(Promega, Madison, WI, USA) according to the manufacturer’s
instructions. Cells were harvested by incubating in trypsin-EDTA
(Sigma) at 371C until detached and dissociated. Apoptotic cells
were identified using flow cytometry (Beckman Coulter Epics XL
Flow) and the Annexin-V-PE apoptosis detection kit (BD
Pharmingen, Franklin Lakes, NJ, USA) as described by the
manufacturer’s protocol.
RNA purification and reverse transcription
Total RNA was isolated from cells using the RNeasy Plus Mini Kit
(Qiagen, Crawley, UK) by following the manufacturer’s protocol.
The RNA was denatured by heating to 651C for 5min. cDNA was
synthesised from RNA using the Cloned AMV First Strand
Synthesis Kit (Invitrogen) according to the manufacturer’s
instructions.
Quantitative PCR
Quantitative PCR was performed using the Stratagene MX3005P
real-time PCR machine and the Brilliant SYBR Green QPCR Master
Mix (Stratagene, La Jolla, CA, USA). Oligonucleotide primers were
designed to facilitate the unique amplification of b-actin, c-Fos and
each HOX gene.
Transcriptional profiling
Total RNA was extracted from A549 cells treated with CXR9 or
HXR9 (60mM) for 3h, and was used as a template to generate Cy3-
labelled cRNA using the Low RNA Input Linear Amplification Kit
(Agilent, Santa Clara, CA, USA). Each Cy3-cRNA was used as
a probe on the Whole Human Genome Microarray (4 44K)
slide. This microarray consists of 60-mer oligonucleotides with
sequences representing more than 41000 human genes. The
microarray slides were scanned and data were extracted using
the Agilent Feature Extraction Software (version 9.5.3). Data were
analysed using GeneSpring GX software.
Mice and in vivo trial
All animal experiments were conducted in accordance with the
United Kingdom Co-ordinating Committee on Cancer Research
guidelines for the Welfare of Animals in Experimental Neoplasia
(Workman et al, 1998) and approved by the St George’s Hospital
Medical School Ethical Review Committee. The mice were kept in
positive pressure isolators in 12h light/dark cycles and food and
water were made available ad libitum.
Athymic nude mice were inoculated subcutaneously with a
suspension of 2.5 10
6 A549 cells in culture media (100ml). Once
tumours reached volumes of approximately 100mm
3, mice
received an initial dose of 100mgkg
 1 CXR9 or HXR9 either
intraperitoneally or intratumorally, with subsequent dosing of
10mgkg
 1 twice weekly. Each group contained 10 mice. The mice
were monitored carefully for signs of distress, including beha-
vioural changes and weight loss. Animals were euthanised if the
tumour volume exceeded 400mm
3.
Statistical analysis of the data
Data are given as means±s.e.m. of multiple independent
experiments. Significant effects were determined using Student’s
t-test.
RESULTS
HOX gene expression in NSCLC
The HOX proteins of paralogue groups 1–9 bind the co-factor PBX
and are thus potential targets of HXR9. To examine the expression
of HOX genes in these paralogue groups, RNA was extracted from
three separate cultures of A549 and H23 together with six primary
NSCLC tumours retrieved during biopsy and corresponding
normal adjacent tissue. Quantitative PCR was used to assess the
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Figure 1 HOX gene expression in primary lung NSCLC tumours, normal adjacent tissue (NAT) and derived cell lines. The expression of each HOX gene
was determined by Q-PCR and is presented as a ratio to the amount of b-actin transcript ( 1000). Error bars show the s.e.m.
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srelative numbers of HOX transcripts. Differences in transcription
are apparent for many of the HOX genes (Figure 1). Notably, a
number of genes in the HOXA group are strongly expressed in
normal tissue, but are downregulated in both primary tumours
and A549, including HOXA3 and HOXA5. Conversely, many
members of the HOXC and HOXD groups are strongly upregulated
in the primary tumours and A549, including HOXC4, HOXC8,
HOXC9, HOXC13, HOXD8 and HOXD10. H23 cells also express
HOX genes but to a considerably lesser degree than the other cell
types studied.
Disrupting the interaction between HOX and PBX triggers
apoptosis in NSCLC cells
The high levels of HOX expression in NSCLC together with the
potential oncogenic function of HOX genes (Eklund, 2007) suggest
that they may be a therapeutic target in this disease. However, the
high level of functional redundancy exhibited by the HOX
transcription factors, together with our observation that many
different HOX genes are expressed, makes a conventional genetic
knockdown approach difficult to use. For this reason, we chose to
target the interaction between HOX proteins and the PBX
co-factor. HOX/PBX dimers have an enhanced binding affinity
and specificity for DNA and are able to activate or repress the
transcription of a subset of target genes (Phelan et al, 1994; Piper
et al, 1999; Morgan et al, 2000). Dimerisation is mediated by a
six-amino-acid region found in the majority of HOX proteins (the
‘hexapeptide’ motif (Piper et al, 1999)). A peptide mimic of this
region linked to a polyarginine sequence (that facilitates cell entry
(Jiang et al, 2004)) might act as a competitive inhibitor of HOX/
PBX binding. We therefore synthesised a peptide that consists of
the hexapeptide sequence linked to nine arginine residues (HXR9)
and a control peptide lacking a functional hexapeptide sequence
(CXR9). Using a fluorescently tagged version of HXR9, we
demonstrated that the peptide was taken up by NSCLC cells in
culture and became concentrated in the nucleus within 2h of
application (Figure 2A).
To determine whether HXR9 can specifically disrupt HOX/PBX
formation (and consequently DNA binding), we studied the effects
of HXR9 on HOXA2 expression. HOXA2, like a number of other
HOX genes, is positively regulated by binding of HOX/PBX
proteins to consensus sequences in the HOXA2 promoter (Tu ¨mpel
et al, 2007). Hence, if HXR9 can disrupt this interaction, it should
reduce HOXA2 expression, which it does (Figure 2B). To show that
HXR9 actually prevents the interaction between HOX and PBX
proteins we used chromatin immune precipitation analysis of
HXR9- and CXR9-treated H23 cells. The presence of the HOX/
PBX-binding site in the HOXA2 promoter results in the enrich-
ment of this sequence when chromatin is selected using either an
anti-HOXA2 or an anti-PBX2 antibody. However, pre-treatment of
cells with HXR9, but not CXR9, causes a significant reduction in
the number of HOXA2 promoter copies recovered using this
technique (Figure 2C), indicating that HXR9 does indeed directly
disrupt the formation of a HOX/PBX complex.
Given the high level of HOX expression in primary tumours and
A549 and H23 cells, we investigated whether HXR9 could trigger
cell death in a similar manner to that observed for melanoma cells
(Morgan et al, 2007). Treatment of cultures with HXR9 (60mM) for
3h resulted in a high degree of cell death whereas CXR9 had no
discernable effects. The IC50 (24h) for HXR9 was determined to be
32.5mM (s.e.m. 0.6mM) in A549 and 69mM (s.e.m. 1.2mM) in H23,
whereas that for CXR9 was in excess of 200mM in both cell lines
(data not shown).
To distinguish between apoptotic and necrotic death, cells were
analysed using flow cytometric analysis after labelling with the
vital dye 7-Amino-actinomycin D (7-AAD) or Annexin-V-FITC.
7-Amino-actinomycin D can enter only dead cells, whereas
Annexin-V-FITC recognises changes in the plasma membrane
that are characteristic of apoptosis (Koopman et al, 1994). A
substantial number of A549 cells treated with HXR9 (60mM) were
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Figure 2 HXR9 blocks HOX/PBX dimer formation in NSCLC cells. (A) HXR9 uptake by A549 cells. A fluorescent micrograph of A549 cells incubated
with 15mM HXR9-FITC (green) for 2h, combined with the corresponding phase-contrast image. HXR9 is primarily located in the nucleus. (B) HOXA2
expression is maintained in part through a HOX/PBX-binding site in its promoter. Correspondingly, Q-PCR analysis of H23 cells treated with 60mM HXR9
for 2h reveals that HOXA2 expression is significantly reduced upon HXR9 treatment. (C) ChIP analysis of the HOXA2 promoter. Chromatin was extracted
from HXR9- or CXR9-treated cells. After cleavage, fragments were immunoprecipitated using an anti-HOXA2 or an anti-PBX antibody, and the number of
copies of the HOXA2 promoter region recovered was determined by Q-PCR. A reduced number of HOXA2 promoter sequences is recovered from HXR9-
treated cells when immunoprecipitating with anti-HOXA2 or anti-PBX antibodies, whereas no significant difference is apparent when equal amounts of
chromatin are used without selection.
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sshown to be undergoing some form of cell death (Figure 3A
and B). When compared with untreated or CXR9-treated cells, a
significant proportion of HXR9-treated cells (Po0.005) were in
either early or late apoptosis, or were necrotic (Po0.05). Similar
changes were also observed for H23 cells (Figure 3C).
HXR9 causes transcriptional changes
To study the transcriptional changes that occur when HOX/PBX
dimers are disrupted by HXR9 we profiled the transcriptome of
CXR9- and HXR9-treated cells using a whole human genome
microarray. RNA was extracted from A549 cells treated with 60mM
HXR9 or CXR9 for 3h and used as a template to generate Cy3-
labelled cRNA for microarray screening. This revealed that a
number of genes were highly upregulated, including a number that
had earlier been observed in melanoma cells (Morgan et al, 2007).
Most significant among these were vFos and FosB, both of which
were upregulated more than five-fold in HXR9-treated cells
compared with controls (Figure 4A). The relative magnitude of
these changes was confirmed using semi-quantitative PCR
(Figure 4B).
HXR9 blocks A549 tumour growth in vivo
To establish whether HXR9 could block A549 tumour growth in
vivo, A549 flank tumours were established in nude mice. When
these had reached an average volume of 100mm
3, twice weekly
treatments of HXR9 or CXR9 were administered by injection
directly either into the tumour or into the peritoneum. After 18
days of treatment, the tumours of HXR9-treated mice were
considerably smaller than those of the control groups
(Figure 5A), and histological analysis revealed changes in tumour
architecture consistent with widespread cell death (Figure 5B).
DISCUSSION
The HOX genes are well established as having oncogenic potential
in a range of haematological malignancies (Eklund, 2007), and
recent studies have indicated that they also allow cell survival in
melanoma by blocking the transcription of pro-apoptotic genes
(Morgan et al, 2007). Here we have shown that disrupting the
interaction between HOX and PBX proteins is sufficient to cause
apoptosis in the NSCLC-derived cell lines, A549 and H23. Although
earlier studies have also shown HOX genes to be dysregulated in
NSCLC (Abe et al, 2006), to our knowledge this is the first report to
describe these changes in a comprehensive manner allowing a
direct comparison between expression in normal lung tissue,
primary tumours and derived cell lines. This reveals that there is a
large increase in transcription in most HOX genes of the HOXC
and HOXD families when comparing normal lung tumour with
primary tumours, and furthermore, this change is also present in
A549 and H23, indicating that there has been a stable change in the
transcriptome.
Analysis of changes in transcription upon the addition of HXR9
revealed that the Early Growth Response 1 (EGR1) gene is
upregulated by more than 20-fold. EGR1 has been shown to
mediate apoptosis in a number of malignancies (Pignatelli et al,
2003; Yu et al, 2007), possibly by activating the transcription of
pro-apoptotic genes such as PTEN, and EGR1 can also block
angiogenesis and tumour invasion (Lucerna et al, 2006; Yu et al,
2007). Further, high levels of EGR1 correlate with improved
survival in NSCLC patients (Ferraro et al, 2005) and is upregulated
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Figure 3 HXR9 triggers apoptosis in A549 and H23 NSCLC cells. Flow cytometric analysis of Annexin-V-PE-stained A549 and H23 cells demonstrated
induction of apoptosis in cultures treated with HXR9. Data are the mean±s.e.m. of four independent experiments. *Po0.05, significantly different from
CXR9-treated cells; **Po0.005, highly significantly different from CXR9-treated cells; ***Po0.0001, extremely significantly different from CXR9-treated
cells. (A) Example plots of flow cytometric data for untreated and HXR9-treated A549 cells. x axis – Annexin-V staining indicating degree of apoptotic
changes in the cell membrane; y axis – 7-AAD vital dye counterstaining as a measure of cell permeability. (B) Summary of flow cytometry data for A549 cells
and (C) for H23 cells. Error bars represent the s.d. (n¼4); ‘V’ – viable cells not in apoptosis, ‘EA’ – cells in early apoptosis, ‘LA’ – cells in late apoptosis and
‘N’ – necrotic cells.
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Figure 4 HXR9 causes transcriptional changes. (A) Subsequent to treatment with CXR9 or HXR9, RNA was extracted from A549 cells and analysed by
microarray. There was no significant change in the transcription of the majority of genes, although five of them showed an increase, and eight a decrease, of
five-fold or greater. (B) Semi-quantitative PCR was used to confirm the microarray findings. Gene expression was determined relative to b-actin expression
and results are presented as a ratio with the expression of each gene in untreated cells. Error bars represent the s.e. of the mean.
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swhen NSCLC cells are treated with the apoptosis-inducing retinoid
6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic
acid (Sakaue et al, 2001).
It is also noteworthy that HXR9-treated A549 cells show a large
increase in the transcription of vFos, cFos and FosB. A similar
response is apparent in melanoma cells in which a large increase in
cFos transcription mediates the pro-apoptotic effect of HXR9
(Morgan et al, 2007). cFos and its binding partner Jun are both
members of the bZIP superfamily of transcription factors, which
are characterised by a basic DNA-binding domain combined with
a leucine zipper region (Hess et al, 2004). JUN can homodimerise
to form the AP-1 transcription factor, which activates the
expression of a number of genes involved in cell cycle regulation,
including cyclin D1 (Albanese et al, 1995). However, an elevated
cFos expression can also lead to apoptosis in hepatoma cells
(Kalra and Kumar, 2004) and hepatocytes (Mikula et al, 2003).
Furthermore, recent studies have shown that cFos transcriptionally
represses the key antiapoptotic gene c-FLIP(L), greatly sensitising
prostate cancer cells to TRAIL-induced apoptosis (Li et al, 2007;
Zhang et al, 2007). Hence strategies to increase cFos transcription
could be valuable in making malignant cells vulnerable to
apoptosis, and HXR9 may synergise with TRAIL and other drugs
that induce apoptosis to facilitate enhanced cell killing across a
broad range of tumour types.
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